ERβ Selective Cycloalkane Compounds for Memory Consolidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ERβ agonists face challenges in selectivity for ERβ over ERα, with existing compounds often having synthetic and stereochemistry issues, and there is a need for more effective treatments for age-related memory decline in post-menopausal women without the risks associated with ERα agonist activity.
Innovation Solution
Development of substituted (4′-hydroxylphenyl) cycloalkane and (4′-hydroxylphenyl) cycloalkene compounds, such as ISP358-2, which exhibit high selectivity for ERβ over ERα, formulated as pharmaceutical compositions to treat diseases associated with ERβ activity, including memory consolidation issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ERβ agonist compounds are used, then some ERβ activity is achieved, but selectivity for ERβ over ERα is insufficient and synthetic complexity increases
Solution Approach 1:
The patent divides the estrogen receptor ligand into two distinct functional segments: a phenolic ring system (A-ring) that provides ERβ selectivity through specific hydrogen bonding interactions, and a cycloalkane or cycloalkene core (B-ring equivalent) that provides structural stability and metabolic stability. This segmentation allows each part to be optimized independently for its specific function.
Solution Approach 2:
The patent extracts and simplifies the essential pharmacophore elements from complex natural estrogens and existing synthetic ERβ agonists. By removing unnecessary aromatic rings and focusing on the critical phenolic A-ring and cycloalkane B-ring interaction, the patent creates a simplified molecule that maintains ERβ selectivity while reducing synthetic complexity.
2Reliability
If ERα agonist activity is used to treat memory decline, then memory consolidation is enhanced, but peripheral toxicity and cancer risks increase
Solution Approach 1:
The patent applies local quality by creating molecular features that are specifically recognized by ERβ but not by ERα. The phenolic ring system with specific substitution patterns and the cycloalkane core create a local molecular environment that selectively activates ERβ in the hippocampus while avoiding ERα activation in peripheral tissues, thus achieving memory benefits without peripheral toxicity.
Solution Approach 2:
The patent converts the potential harm of non-selective estrogen therapy (which causes peripheral toxicity and cancer risk through ERα activation) into a benefit by designing a molecule that selectively activates only ERβ. This transforms the problem of ERα-mediated side effects into a solution where only the beneficial ERβ pathway is activated.
3Reliability
If complex aromatic ring systems are used in ERβ agonists, then binding affinity is improved, but synthetic difficulty and stereochemistry issues increase
Solution Approach 1:
Instead of starting with complex aromatic ring systems and trying to simplify them, the patent inverts the approach by starting with a simple cycloalkane or cycloalkene core and adding only the essential phenolic A-ring functionality. This inversion of the synthetic planning approach makes the synthesis more straightforward while maintaining binding affinity.
Solution Approach 2:
The patent changes the fundamental structural parameter from aromatic B-ring systems to saturated or unsaturated cycloalkane/cycloalkene cores. This parameter change maintains the essential pharmacological interactions at the phenolic A-ring while dramatically simplifying the rest of the molecule, making it easier to synthesize and control stereochemistry.
Data Source
AI summary
Disclosed are substituted (4′-hydroxylphenyl) cycloalkane compounds and substituted (4′-hydroxylphenyl) cycloalkene compounds and there use as selective agonists of the estrogen receptor beta isoform (ERβ). The disclosed compounds may be formulated as pharmaceutical compositions and administered for treating diseases associated with ER activity, such as neurological, psychiatric, and/or cell proliferative diseases and disorders as well as for enhancing memory consolidation in subjects in need thereof.